nodes	percent_of_prediction	percent_of_DWPC	metapath
Efavirenz—CYP1A2—Carmustine—lymphatic system cancer	0.183	0.289	CbGbCtD
Efavirenz—CYP2C19—Teniposide—lymphatic system cancer	0.134	0.211	CbGbCtD
Efavirenz—CYP2C9—Teniposide—lymphatic system cancer	0.111	0.175	CbGbCtD
Efavirenz—CYP3A4—Cytarabine—lymphatic system cancer	0.0655	0.103	CbGbCtD
Efavirenz—CYP3A4—Teniposide—lymphatic system cancer	0.0646	0.102	CbGbCtD
Efavirenz—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0452	0.0712	CbGbCtD
Efavirenz—CYP3A4—Vincristine—lymphatic system cancer	0.0311	0.049	CbGbCtD
Efavirenz—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00065	0.00178	CcSEcCtD
Efavirenz—Asthenia—Teniposide—lymphatic system cancer	0.000644	0.00176	CcSEcCtD
Efavirenz—Malaise—Bleomycin—lymphatic system cancer	0.000639	0.00175	CcSEcCtD
Efavirenz—Pruritus—Teniposide—lymphatic system cancer	0.000635	0.00174	CcSEcCtD
Efavirenz—Arrhythmia—Carmustine—lymphatic system cancer	0.000635	0.00174	CcSEcCtD
Efavirenz—Depressed level of consciousness—Methotrexate—lymphatic system cancer	0.000633	0.00173	CcSEcCtD
Efavirenz—Cardiac disorder—Vincristine—lymphatic system cancer	0.00063	0.00172	CcSEcCtD
Efavirenz—Alopecia—Carmustine—lymphatic system cancer	0.000628	0.00172	CcSEcCtD
Efavirenz—Skin exfoliation—Methotrexate—lymphatic system cancer	0.000626	0.00171	CcSEcCtD
Efavirenz—Body temperature increased—Fludarabine—lymphatic system cancer	0.000624	0.00171	CcSEcCtD
Efavirenz—Erythema—Carmustine—lymphatic system cancer	0.000619	0.00169	CcSEcCtD
Efavirenz—Malnutrition—Carmustine—lymphatic system cancer	0.000619	0.00169	CcSEcCtD
Efavirenz—Cough—Bleomycin—lymphatic system cancer	0.000619	0.00169	CcSEcCtD
Efavirenz—Angiopathy—Vincristine—lymphatic system cancer	0.000616	0.00168	CcSEcCtD
Efavirenz—Diarrhoea—Teniposide—lymphatic system cancer	0.000614	0.00168	CcSEcCtD
Efavirenz—Mediastinal disorder—Vincristine—lymphatic system cancer	0.000612	0.00167	CcSEcCtD
Efavirenz—Chest pain—Bleomycin—lymphatic system cancer	0.000604	0.00165	CcSEcCtD
Efavirenz—Myalgia—Bleomycin—lymphatic system cancer	0.000604	0.00165	CcSEcCtD
Efavirenz—Alopecia—Vincristine—lymphatic system cancer	0.0006	0.00164	CcSEcCtD
Efavirenz—Back pain—Carmustine—lymphatic system cancer	0.000599	0.00164	CcSEcCtD
Efavirenz—Discomfort—Bleomycin—lymphatic system cancer	0.000596	0.00163	CcSEcCtD
Efavirenz—Urine output increased—Methotrexate—lymphatic system cancer	0.000593	0.00162	CcSEcCtD
Efavirenz—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.00059	0.00161	CcSEcCtD
Efavirenz—Gynaecomastia—Methotrexate—lymphatic system cancer	0.000587	0.0016	CcSEcCtD
Efavirenz—Alopecia—Mitoxantrone—lymphatic system cancer	0.000584	0.0016	CcSEcCtD
Efavirenz—Confusional state—Bleomycin—lymphatic system cancer	0.000583	0.0016	CcSEcCtD
Efavirenz—Vision blurred—Carmustine—lymphatic system cancer	0.000583	0.00159	CcSEcCtD
Efavirenz—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000581	0.00159	CcSEcCtD
Efavirenz—Tremor—Carmustine—lymphatic system cancer	0.00058	0.00159	CcSEcCtD
Efavirenz—Erythema—Mitoxantrone—lymphatic system cancer	0.000575	0.00157	CcSEcCtD
Efavirenz—Anaemia—Carmustine—lymphatic system cancer	0.000572	0.00156	CcSEcCtD
Efavirenz—Back pain—Vincristine—lymphatic system cancer	0.000571	0.00156	CcSEcCtD
Efavirenz—Vomiting—Teniposide—lymphatic system cancer	0.000571	0.00156	CcSEcCtD
Efavirenz—Agitation—Carmustine—lymphatic system cancer	0.000569	0.00155	CcSEcCtD
Efavirenz—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000566	0.00155	CcSEcCtD
Efavirenz—Asthenia—Fludarabine—lymphatic system cancer	0.000566	0.00155	CcSEcCtD
Efavirenz—Rash—Teniposide—lymphatic system cancer	0.000566	0.00155	CcSEcCtD
Efavirenz—Dermatitis—Teniposide—lymphatic system cancer	0.000566	0.00155	CcSEcCtD
Efavirenz—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000563	0.00154	CcSEcCtD
Efavirenz—Headache—Teniposide—lymphatic system cancer	0.000562	0.00154	CcSEcCtD
Efavirenz—Pruritus—Fludarabine—lymphatic system cancer	0.000558	0.00153	CcSEcCtD
Efavirenz—Back pain—Mitoxantrone—lymphatic system cancer	0.000556	0.00152	CcSEcCtD
Efavirenz—Anorexia—Bleomycin—lymphatic system cancer	0.000551	0.00151	CcSEcCtD
Efavirenz—Thrombophlebitis—Methotrexate—lymphatic system cancer	0.00055	0.0015	CcSEcCtD
Efavirenz—Anaemia—Vincristine—lymphatic system cancer	0.000546	0.00149	CcSEcCtD
Efavirenz—Agitation—Vincristine—lymphatic system cancer	0.000543	0.00148	CcSEcCtD
Efavirenz—Vision blurred—Mitoxantrone—lymphatic system cancer	0.000542	0.00148	CcSEcCtD
Efavirenz—Polyuria—Methotrexate—lymphatic system cancer	0.000542	0.00148	CcSEcCtD
Efavirenz—Diarrhoea—Fludarabine—lymphatic system cancer	0.00054	0.00148	CcSEcCtD
Efavirenz—Convulsion—Carmustine—lymphatic system cancer	0.000536	0.00147	CcSEcCtD
Efavirenz—Hypertension—Carmustine—lymphatic system cancer	0.000534	0.00146	CcSEcCtD
Efavirenz—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000534	0.00146	CcSEcCtD
Efavirenz—Nausea—Teniposide—lymphatic system cancer	0.000533	0.00146	CcSEcCtD
Efavirenz—Anaemia—Mitoxantrone—lymphatic system cancer	0.000532	0.00145	CcSEcCtD
Efavirenz—Vertigo—Vincristine—lymphatic system cancer	0.000531	0.00145	CcSEcCtD
Efavirenz—Hepatic failure—Methotrexate—lymphatic system cancer	0.00053	0.00145	CcSEcCtD
Efavirenz—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000527	0.00144	CcSEcCtD
Efavirenz—Myalgia—Carmustine—lymphatic system cancer	0.000527	0.00144	CcSEcCtD
Efavirenz—Chest pain—Carmustine—lymphatic system cancer	0.000527	0.00144	CcSEcCtD
Efavirenz—Anxiety—Carmustine—lymphatic system cancer	0.000525	0.00144	CcSEcCtD
Efavirenz—Paraesthesia—Bleomycin—lymphatic system cancer	0.00052	0.00142	CcSEcCtD
Efavirenz—Malaise—Mitoxantrone—lymphatic system cancer	0.000519	0.00142	CcSEcCtD
Efavirenz—Dyspnoea—Bleomycin—lymphatic system cancer	0.000516	0.00141	CcSEcCtD
Efavirenz—Renal failure acute—Methotrexate—lymphatic system cancer	0.000515	0.00141	CcSEcCtD
Efavirenz—Convulsion—Vincristine—lymphatic system cancer	0.000512	0.0014	CcSEcCtD
Efavirenz—Hypertension—Vincristine—lymphatic system cancer	0.00051	0.00139	CcSEcCtD
Efavirenz—Confusional state—Carmustine—lymphatic system cancer	0.000509	0.00139	CcSEcCtD
Efavirenz—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	0.000504	0.00138	CcSEcCtD
Efavirenz—Decreased appetite—Bleomycin—lymphatic system cancer	0.000503	0.00138	CcSEcCtD
Efavirenz—Myalgia—Vincristine—lymphatic system cancer	0.000503	0.00138	CcSEcCtD
Efavirenz—Cough—Mitoxantrone—lymphatic system cancer	0.000502	0.00137	CcSEcCtD
Efavirenz—Vomiting—Fludarabine—lymphatic system cancer	0.000502	0.00137	CcSEcCtD
Efavirenz—Convulsion—Mitoxantrone—lymphatic system cancer	0.000498	0.00136	CcSEcCtD
Efavirenz—Rash—Fludarabine—lymphatic system cancer	0.000498	0.00136	CcSEcCtD
Efavirenz—Dermatitis—Fludarabine—lymphatic system cancer	0.000497	0.00136	CcSEcCtD
Efavirenz—Hypertension—Mitoxantrone—lymphatic system cancer	0.000497	0.00136	CcSEcCtD
Efavirenz—Pain—Bleomycin—lymphatic system cancer	0.000495	0.00135	CcSEcCtD
Efavirenz—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000494	0.00135	CcSEcCtD
Efavirenz—Headache—Fludarabine—lymphatic system cancer	0.000494	0.00135	CcSEcCtD
Efavirenz—Tachycardia—Carmustine—lymphatic system cancer	0.000493	0.00135	CcSEcCtD
Efavirenz—Myalgia—Mitoxantrone—lymphatic system cancer	0.00049	0.00134	CcSEcCtD
Efavirenz—Chest pain—Mitoxantrone—lymphatic system cancer	0.00049	0.00134	CcSEcCtD
Efavirenz—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00049	0.00134	CcSEcCtD
Efavirenz—Anxiety—Mitoxantrone—lymphatic system cancer	0.000488	0.00133	CcSEcCtD
Efavirenz—Discomfort—Mitoxantrone—lymphatic system cancer	0.000484	0.00132	CcSEcCtD
Efavirenz—Anorexia—Carmustine—lymphatic system cancer	0.000481	0.00132	CcSEcCtD
Efavirenz—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000477	0.0013	CcSEcCtD
Efavirenz—Confusional state—Mitoxantrone—lymphatic system cancer	0.000473	0.00129	CcSEcCtD
Efavirenz—Nervous system disorder—Vincristine—lymphatic system cancer	0.000473	0.00129	CcSEcCtD
Efavirenz—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000472	0.00129	CcSEcCtD
Efavirenz—Nausea—Fludarabine—lymphatic system cancer	0.000469	0.00128	CcSEcCtD
Efavirenz—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000466	0.00127	CcSEcCtD
Efavirenz—Shock—Mitoxantrone—lymphatic system cancer	0.000462	0.00126	CcSEcCtD
Efavirenz—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00046	0.00126	CcSEcCtD
Efavirenz—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00046	0.00126	CcSEcCtD
Efavirenz—Urticaria—Bleomycin—lymphatic system cancer	0.00046	0.00126	CcSEcCtD
Efavirenz—Anorexia—Vincristine—lymphatic system cancer	0.00046	0.00126	CcSEcCtD
Efavirenz—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000458	0.00125	CcSEcCtD
Efavirenz—Body temperature increased—Bleomycin—lymphatic system cancer	0.000457	0.00125	CcSEcCtD
Efavirenz—Insomnia—Carmustine—lymphatic system cancer	0.000457	0.00125	CcSEcCtD
Efavirenz—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000456	0.00125	CcSEcCtD
Efavirenz—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000454	0.00124	CcSEcCtD
Efavirenz—Paraesthesia—Carmustine—lymphatic system cancer	0.000453	0.00124	CcSEcCtD
Efavirenz—Mood swings—Methotrexate—lymphatic system cancer	0.000451	0.00123	CcSEcCtD
Efavirenz—Dyspnoea—Carmustine—lymphatic system cancer	0.00045	0.00123	CcSEcCtD
Efavirenz—Somnolence—Carmustine—lymphatic system cancer	0.000449	0.00123	CcSEcCtD
Efavirenz—Anorexia—Mitoxantrone—lymphatic system cancer	0.000448	0.00122	CcSEcCtD
Efavirenz—Ataxia—Methotrexate—lymphatic system cancer	0.000448	0.00122	CcSEcCtD
Efavirenz—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000439	0.0012	CcSEcCtD
Efavirenz—Decreased appetite—Carmustine—lymphatic system cancer	0.000439	0.0012	CcSEcCtD
Efavirenz—Insomnia—Vincristine—lymphatic system cancer	0.000436	0.00119	CcSEcCtD
Efavirenz—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000436	0.00119	CcSEcCtD
Efavirenz—Paraesthesia—Vincristine—lymphatic system cancer	0.000433	0.00118	CcSEcCtD
Efavirenz—Pain—Carmustine—lymphatic system cancer	0.000432	0.00118	CcSEcCtD
Efavirenz—Constipation—Carmustine—lymphatic system cancer	0.000432	0.00118	CcSEcCtD
Efavirenz—Breast disorder—Methotrexate—lymphatic system cancer	0.00043	0.00118	CcSEcCtD
Efavirenz—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.000429	0.00117	CcSEcCtD
Efavirenz—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000428	0.00117	CcSEcCtD
Efavirenz—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000426	0.00117	CcSEcCtD
Efavirenz—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000422	0.00115	CcSEcCtD
Efavirenz—Decreased appetite—Vincristine—lymphatic system cancer	0.000419	0.00115	CcSEcCtD
Efavirenz—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000419	0.00114	CcSEcCtD
Efavirenz—Somnolence—Mitoxantrone—lymphatic system cancer	0.000417	0.00114	CcSEcCtD
Efavirenz—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000416	0.00114	CcSEcCtD
Efavirenz—Feeling abnormal—Carmustine—lymphatic system cancer	0.000416	0.00114	CcSEcCtD
Efavirenz—Fatigue—Vincristine—lymphatic system cancer	0.000416	0.00114	CcSEcCtD
Efavirenz—Asthenia—Bleomycin—lymphatic system cancer	0.000415	0.00113	CcSEcCtD
Efavirenz—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000413	0.00113	CcSEcCtD
Efavirenz—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000413	0.00113	CcSEcCtD
Efavirenz—Constipation—Vincristine—lymphatic system cancer	0.000412	0.00113	CcSEcCtD
Efavirenz—Pain—Vincristine—lymphatic system cancer	0.000412	0.00113	CcSEcCtD
Efavirenz—Asthma—Methotrexate—lymphatic system cancer	0.000411	0.00112	CcSEcCtD
Efavirenz—Pruritus—Bleomycin—lymphatic system cancer	0.000409	0.00112	CcSEcCtD
Efavirenz—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000408	0.00112	CcSEcCtD
Efavirenz—Fatigue—Mitoxantrone—lymphatic system cancer	0.000405	0.00111	CcSEcCtD
Efavirenz—Pancreatitis—Methotrexate—lymphatic system cancer	0.000403	0.0011	CcSEcCtD
Efavirenz—Constipation—Mitoxantrone—lymphatic system cancer	0.000401	0.0011	CcSEcCtD
Efavirenz—Pain—Mitoxantrone—lymphatic system cancer	0.000401	0.0011	CcSEcCtD
Efavirenz—Abdominal pain—Carmustine—lymphatic system cancer	0.000399	0.00109	CcSEcCtD
Efavirenz—Body temperature increased—Carmustine—lymphatic system cancer	0.000399	0.00109	CcSEcCtD
Efavirenz—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000394	0.00108	CcSEcCtD
Efavirenz—Pancytopenia—Methotrexate—lymphatic system cancer	0.000391	0.00107	CcSEcCtD
Efavirenz—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000387	0.00106	CcSEcCtD
Efavirenz—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000384	0.00105	CcSEcCtD
Efavirenz—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.000382	0.00105	CcSEcCtD
Efavirenz—Abdominal pain—Vincristine—lymphatic system cancer	0.000381	0.00104	CcSEcCtD
Efavirenz—Body temperature increased—Vincristine—lymphatic system cancer	0.000381	0.00104	CcSEcCtD
Efavirenz—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000375	0.00103	CcSEcCtD
Efavirenz—Urticaria—Mitoxantrone—lymphatic system cancer	0.000373	0.00102	CcSEcCtD
Efavirenz—Hypersensitivity—Carmustine—lymphatic system cancer	0.000372	0.00102	CcSEcCtD
Efavirenz—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000371	0.00101	CcSEcCtD
Efavirenz—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000371	0.00101	CcSEcCtD
Efavirenz—Pneumonia—Methotrexate—lymphatic system cancer	0.000369	0.00101	CcSEcCtD
Efavirenz—Vomiting—Bleomycin—lymphatic system cancer	0.000368	0.00101	CcSEcCtD
Efavirenz—Infestation—Methotrexate—lymphatic system cancer	0.000367	0.001	CcSEcCtD
Efavirenz—Infestation NOS—Methotrexate—lymphatic system cancer	0.000367	0.001	CcSEcCtD
Efavirenz—Drowsiness—Methotrexate—lymphatic system cancer	0.000367	0.001	CcSEcCtD
Efavirenz—Depression—Methotrexate—lymphatic system cancer	0.000366	0.001	CcSEcCtD
Efavirenz—Rash—Bleomycin—lymphatic system cancer	0.000365	0.000997	CcSEcCtD
Efavirenz—Dermatitis—Bleomycin—lymphatic system cancer	0.000364	0.000996	CcSEcCtD
Efavirenz—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.000364	0.000994	CcSEcCtD
Efavirenz—Asthenia—Carmustine—lymphatic system cancer	0.000362	0.000991	CcSEcCtD
Efavirenz—Renal failure—Methotrexate—lymphatic system cancer	0.000361	0.000986	CcSEcCtD
Efavirenz—Hypersensitivity—Vincristine—lymphatic system cancer	0.000355	0.000971	CcSEcCtD
Efavirenz—Sweating—Methotrexate—lymphatic system cancer	0.000352	0.000961	CcSEcCtD
Efavirenz—Haematuria—Methotrexate—lymphatic system cancer	0.00035	0.000956	CcSEcCtD
Efavirenz—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000347	0.000948	CcSEcCtD
Efavirenz—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000346	0.000946	CcSEcCtD
Efavirenz—Asthenia—Vincristine—lymphatic system cancer	0.000346	0.000946	CcSEcCtD
Efavirenz—Diarrhoea—Carmustine—lymphatic system cancer	0.000346	0.000945	CcSEcCtD
Efavirenz—Nausea—Bleomycin—lymphatic system cancer	0.000344	0.00094	CcSEcCtD
Efavirenz—Asthenia—Mitoxantrone—lymphatic system cancer	0.000337	0.000921	CcSEcCtD
Efavirenz—Dizziness—Carmustine—lymphatic system cancer	0.000334	0.000913	CcSEcCtD
Efavirenz—Diarrhoea—Vincristine—lymphatic system cancer	0.00033	0.000902	CcSEcCtD
Efavirenz—Hepatitis—Methotrexate—lymphatic system cancer	0.000329	0.0009	CcSEcCtD
Efavirenz—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000325	0.000889	CcSEcCtD
Efavirenz—Urethral disorder—Methotrexate—lymphatic system cancer	0.000323	0.000882	CcSEcCtD
Efavirenz—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000321	0.000878	CcSEcCtD
Efavirenz—Vomiting—Carmustine—lymphatic system cancer	0.000321	0.000878	CcSEcCtD
Efavirenz—Dizziness—Vincristine—lymphatic system cancer	0.000319	0.000872	CcSEcCtD
Efavirenz—Rash—Carmustine—lymphatic system cancer	0.000318	0.000871	CcSEcCtD
Efavirenz—Dermatitis—Carmustine—lymphatic system cancer	0.000318	0.00087	CcSEcCtD
Efavirenz—Visual impairment—Methotrexate—lymphatic system cancer	0.000317	0.000868	CcSEcCtD
Efavirenz—Headache—Carmustine—lymphatic system cancer	0.000316	0.000865	CcSEcCtD
Efavirenz—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000311	0.000851	CcSEcCtD
Efavirenz—Eye disorder—Methotrexate—lymphatic system cancer	0.000308	0.000841	CcSEcCtD
Efavirenz—Tinnitus—Methotrexate—lymphatic system cancer	0.000307	0.000839	CcSEcCtD
Efavirenz—Vomiting—Vincristine—lymphatic system cancer	0.000307	0.000838	CcSEcCtD
Efavirenz—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000306	0.000835	CcSEcCtD
Efavirenz—Rash—Vincristine—lymphatic system cancer	0.000304	0.000831	CcSEcCtD
Efavirenz—Dermatitis—Vincristine—lymphatic system cancer	0.000304	0.00083	CcSEcCtD
Efavirenz—Headache—Vincristine—lymphatic system cancer	0.000302	0.000826	CcSEcCtD
Efavirenz—Nausea—Carmustine—lymphatic system cancer	0.0003	0.00082	CcSEcCtD
Efavirenz—Angiopathy—Methotrexate—lymphatic system cancer	0.000299	0.000817	CcSEcCtD
Efavirenz—Vomiting—Mitoxantrone—lymphatic system cancer	0.000299	0.000816	CcSEcCtD
Efavirenz—Immune system disorder—Methotrexate—lymphatic system cancer	0.000297	0.000813	CcSEcCtD
Efavirenz—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000297	0.000811	CcSEcCtD
Efavirenz—Rash—Mitoxantrone—lymphatic system cancer	0.000296	0.000809	CcSEcCtD
Efavirenz—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000296	0.000809	CcSEcCtD
Efavirenz—Headache—Mitoxantrone—lymphatic system cancer	0.000294	0.000804	CcSEcCtD
Efavirenz—Alopecia—Methotrexate—lymphatic system cancer	0.000291	0.000796	CcSEcCtD
Efavirenz—Erythema—Methotrexate—lymphatic system cancer	0.000287	0.000784	CcSEcCtD
Efavirenz—Malnutrition—Methotrexate—lymphatic system cancer	0.000287	0.000784	CcSEcCtD
Efavirenz—Nausea—Vincristine—lymphatic system cancer	0.000286	0.000783	CcSEcCtD
Efavirenz—Dysgeusia—Methotrexate—lymphatic system cancer	0.000281	0.000767	CcSEcCtD
Efavirenz—Nausea—Mitoxantrone—lymphatic system cancer	0.000279	0.000762	CcSEcCtD
Efavirenz—Back pain—Methotrexate—lymphatic system cancer	0.000277	0.000758	CcSEcCtD
Efavirenz—Vision blurred—Methotrexate—lymphatic system cancer	0.00027	0.000739	CcSEcCtD
Efavirenz—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000266	0.000727	CcSEcCtD
Efavirenz—Anaemia—Methotrexate—lymphatic system cancer	0.000265	0.000724	CcSEcCtD
Efavirenz—Malaise—Methotrexate—lymphatic system cancer	0.000258	0.000707	CcSEcCtD
Efavirenz—Vertigo—Methotrexate—lymphatic system cancer	0.000258	0.000704	CcSEcCtD
Efavirenz—Cough—Methotrexate—lymphatic system cancer	0.00025	0.000684	CcSEcCtD
Efavirenz—Convulsion—Methotrexate—lymphatic system cancer	0.000248	0.000679	CcSEcCtD
Efavirenz—Myalgia—Methotrexate—lymphatic system cancer	0.000244	0.000667	CcSEcCtD
Efavirenz—Chest pain—Methotrexate—lymphatic system cancer	0.000244	0.000667	CcSEcCtD
Efavirenz—Arthralgia—Methotrexate—lymphatic system cancer	0.000244	0.000667	CcSEcCtD
Efavirenz—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000242	0.000663	CcSEcCtD
Efavirenz—Discomfort—Methotrexate—lymphatic system cancer	0.000241	0.000659	CcSEcCtD
Efavirenz—Confusional state—Methotrexate—lymphatic system cancer	0.000236	0.000645	CcSEcCtD
Efavirenz—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000229	0.000627	CcSEcCtD
Efavirenz—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000229	0.000626	CcSEcCtD
Efavirenz—Skin disorder—Methotrexate—lymphatic system cancer	0.000227	0.000621	CcSEcCtD
Efavirenz—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000226	0.000618	CcSEcCtD
Efavirenz—Anorexia—Methotrexate—lymphatic system cancer	0.000223	0.00061	CcSEcCtD
Efavirenz—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000213	0.000583	CcSEcCtD
Efavirenz—Insomnia—Methotrexate—lymphatic system cancer	0.000212	0.000578	CcSEcCtD
Efavirenz—Paraesthesia—Methotrexate—lymphatic system cancer	0.00021	0.000574	CcSEcCtD
Efavirenz—Dyspnoea—Methotrexate—lymphatic system cancer	0.000209	0.00057	CcSEcCtD
Efavirenz—Somnolence—Methotrexate—lymphatic system cancer	0.000208	0.000569	CcSEcCtD
Efavirenz—Dyspepsia—Methotrexate—lymphatic system cancer	0.000206	0.000563	CcSEcCtD
Efavirenz—Decreased appetite—Methotrexate—lymphatic system cancer	0.000203	0.000556	CcSEcCtD
Efavirenz—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000202	0.000552	CcSEcCtD
Efavirenz—Fatigue—Methotrexate—lymphatic system cancer	0.000202	0.000551	CcSEcCtD
Efavirenz—Pain—Methotrexate—lymphatic system cancer	0.0002	0.000547	CcSEcCtD
Efavirenz—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000193	0.000527	CcSEcCtD
Efavirenz—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000191	0.000523	CcSEcCtD
Efavirenz—Urticaria—Methotrexate—lymphatic system cancer	0.000186	0.000508	CcSEcCtD
Efavirenz—Abdominal pain—Methotrexate—lymphatic system cancer	0.000185	0.000506	CcSEcCtD
Efavirenz—Body temperature increased—Methotrexate—lymphatic system cancer	0.000185	0.000506	CcSEcCtD
Efavirenz—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000172	0.000471	CcSEcCtD
Efavirenz—Asthenia—Methotrexate—lymphatic system cancer	0.000168	0.000459	CcSEcCtD
Efavirenz—Pruritus—Methotrexate—lymphatic system cancer	0.000165	0.000452	CcSEcCtD
Efavirenz—Diarrhoea—Methotrexate—lymphatic system cancer	0.00016	0.000438	CcSEcCtD
Efavirenz—Dizziness—Methotrexate—lymphatic system cancer	0.000155	0.000423	CcSEcCtD
Efavirenz—Vomiting—Methotrexate—lymphatic system cancer	0.000149	0.000407	CcSEcCtD
Efavirenz—Rash—Methotrexate—lymphatic system cancer	0.000147	0.000403	CcSEcCtD
Efavirenz—Dermatitis—Methotrexate—lymphatic system cancer	0.000147	0.000403	CcSEcCtD
Efavirenz—Headache—Methotrexate—lymphatic system cancer	0.000147	0.000401	CcSEcCtD
Efavirenz—Nausea—Methotrexate—lymphatic system cancer	0.000139	0.00038	CcSEcCtD
